EYPT logo

EyePoint Pharmaceuticals, Inc. (EYPT) EBITDA

annual EBITDA:

-$129.23M-$60.23M(-87.28%)
December 31, 2024

Summary

  • As of today (September 16, 2025), EYPT annual EBITDA is -$129.23 million, with the most recent change of -$60.23 million (-87.28%) on December 31, 2024.
  • During the last 3 years, EYPT annual EBITDA has fallen by -$79.08 million (-157.69%).
  • EYPT annual EBITDA is now -1140.72% below its all-time high of $12.42 million, reached on June 30, 2010.

Performance

EYPT EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEYPTincome statement metrics

quarterly EBITDA:

-$61.69M-$13.35M(-27.61%)
June 30, 2025

Summary

  • As of today (September 16, 2025), EYPT quarterly EBITDA is -$61.69 million, with the most recent change of -$13.35 million (-27.61%) on June 30, 2025.
  • Over the past year, EYPT quarterly EBITDA has dropped by -$27.50 million (-80.46%).
  • EYPT quarterly EBITDA is now -393.48% below its all-time high of $21.02 million, reached on September 30, 2014.

Performance

EYPT quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEYPTincome statement metrics

TTM EBITDA:

-$187.14M-$27.50M(-17.23%)
June 30, 2025

Summary

  • As of today (September 16, 2025), EYPT TTM EBITDA is -$187.14 million, with the most recent change of -$27.50 million (-17.23%) on June 30, 2025.
  • Over the past year, EYPT TTM EBITDA has dropped by -$89.41 million (-91.49%).
  • EYPT TTM EBITDA is now -1607.14% below its all-time high of $12.42 million, reached on June 30, 2010.

Performance

EYPT TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEYPTincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

EYPT EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-87.3%-80.5%-91.5%
3 y3 years-157.7%-233.2%-174.6%
5 y5 years-169.2%-488.5%-334.9%

EYPT EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-157.7%at low-331.9%at low-174.6%at low
5 y5-year-264.1%at low-4663.6%at low-505.5%at low
alltimeall time-1140.7%at low-393.5%at low-1607.1%at low

EYPT EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
-$61.69M(+27.6%)
-$187.14M(+17.2%)
Mar 2025
-
-$48.34M(+8.0%)
-$159.64M(+10.6%)
Dec 2024
-$129.23M(+87.3%)
-$44.77M(+38.4%)
-$144.31M(+24.6%)
Sep 2024
-
-$32.34M(-5.4%)
-$115.78M(+18.5%)
Jun 2024
-
-$34.18M(+3.5%)
-$97.73M(+13.4%)
Mar 2024
-
-$33.02M(+103.3%)
-$86.17M(+15.5%)
Dec 2023
-$69.00M(-28.6%)
-$16.24M(+13.7%)
-$74.60M(-8.0%)
Sep 2023
-
-$14.28M(-36.9%)
-$81.06M(-4.0%)
Jun 2023
-
-$22.63M(+5.5%)
-$84.47M(+5.1%)
Mar 2023
-
-$21.45M(-5.5%)
-$80.35M(+5.0%)
Dec 2022
-$96.62M(+92.7%)
-$22.70M(+28.3%)
-$76.49M(+7.5%)
Sep 2022
-
-$17.69M(-4.5%)
-$71.14M(+4.4%)
Jun 2022
-
-$18.51M(+5.3%)
-$68.15M(+13.7%)
Mar 2022
-
-$17.59M(+1.4%)
-$59.93M(+14.0%)
Dec 2021
-$50.15M(+41.3%)
-$17.35M(+18.1%)
-$52.59M(+11.2%)
Sep 2021
-
-$14.70M(+42.8%)
-$47.31M(+39.5%)
Jun 2021
-
-$10.29M(+0.4%)
-$33.91M(-0.6%)
Mar 2021
-
-$10.25M(-15.1%)
-$34.09M(-1.6%)
Dec 2020
-$35.49M(-26.1%)
-$12.07M(+831.9%)
-$34.64M(+12.1%)
Sep 2020
-
-$1.29M(-87.6%)
-$30.91M(-28.2%)
Jun 2020
-
-$10.48M(-2.9%)
-$43.03M(+2.3%)
Mar 2020
-
-$10.80M(+29.5%)
-$42.06M(-7.1%)
Dec 2019
-$48.01M(+15.0%)
-$8.34M(-37.9%)
-$45.26M(+22.6%)
Sep 2019
-
-$13.41M(+41.0%)
-$36.92M(+57.1%)
Jun 2019
-
-$9.52M(-32.0%)
-$23.51M(+68.0%)
Mar 2019
-
-$13.99M(+136.3%)
-$13.99M(-19.1%)
Dec 2018
-$41.75M(+136.3%)
-
-
Jun 2017
-$17.67M(-15.0%)
-$5.92M(+19.6%)
-$17.29M(-1.6%)
Mar 2017
-
-$4.95M(-3446.6%)
-$17.57M(+0.2%)
Dec 2016
-
$148.00K(-102.3%)
-$17.54M(-22.9%)
Sep 2016
-
-$6.56M(+5.7%)
-$22.74M(+8.4%)
Jun 2016
-$20.79M(-384.7%)
-$6.21M(+26.2%)
-$20.99M(+6.2%)
Mar 2016
-
-$4.92M(-2.7%)
-$19.76M(+0.4%)
Dec 2015
-
-$5.06M(+5.2%)
-$19.68M(+6.2%)
Sep 2015
-
-$4.81M(-3.4%)
-$18.52M(-353.7%)
Jun 2015
$7.30M(-157.7%)
-$4.98M(+2.8%)
$7.30M(-14.1%)
Mar 2015
-
-$4.84M(+24.1%)
$8.50M(-25.1%)
Dec 2014
-
-$3.90M(-118.6%)
$11.35M(-4.3%)
Sep 2014
-
$21.02M(-655.8%)
$11.86M(-193.7%)
Jun 2014
-$12.65M(+14.6%)
-$3.78M(+89.9%)
-$12.65M(+0.4%)
Mar 2014
-
-$1.99M(-41.2%)
-$12.60M(-4.3%)
Dec 2013
-
-$3.39M(-2.8%)
-$13.17M(+8.1%)
Sep 2013
-
-$3.49M(-6.6%)
-$12.18M(+10.4%)
Jun 2013
-$11.04M
-$3.73M(+45.6%)
-$11.04M(+18.1%)
DateAnnualQuarterlyTTM
Mar 2013
-
-$2.56M(+6.9%)
-$9.34M(+0.8%)
Dec 2012
-
-$2.40M(+2.4%)
-$9.27M(+5.1%)
Sep 2012
-
-$2.34M(+14.9%)
-$8.82M(+8.2%)
Jun 2012
-$22.78M(+315.8%)
-$2.04M(-18.1%)
-$8.15M(+46.4%)
Mar 2012
-
-$2.49M(+27.7%)
-$5.57M(+3.6%)
Dec 2011
-
-$1.95M(+16.5%)
-$5.37M(-5.9%)
Sep 2011
-
-$1.67M(-406.0%)
-$5.71M(-14.1%)
Jun 2011
-$5.48M(-144.1%)
$547.00K(-123.8%)
-$6.65M(-215.0%)
Mar 2011
-
-$2.29M(+0.4%)
$5.78M(-4.2%)
Dec 2010
-
-$2.29M(-12.5%)
$6.03M(-33.4%)
Sep 2010
-
-$2.61M(-120.1%)
$9.06M(-27.1%)
Jun 2010
$12.42M(<-9900.0%)
$12.97M(-736.0%)
$12.42M(+5757.1%)
Mar 2010
-
-$2.04M(-377.2%)
$212.00K(-90.6%)
Dec 2009
-
$736.00K(-1.5%)
$2.27M(+136.3%)
Sep 2009
-
$747.00K(-2.9%)
$959.00K(-180.1%)
Jun 2009
-$24.00K(-100.0%)
$769.00K(+5392.9%)
-$1.20M(-79.9%)
Mar 2009
-
$14.00K(-102.5%)
-$5.97M(-48.4%)
Dec 2008
-
-$571.00K(-59.5%)
-$11.57M(-35.5%)
Sep 2008
-
-$1.41M(-64.8%)
-$17.93M(-13.1%)
Jun 2008
-$71.36M(+166.0%)
-$4.01M(-28.2%)
-$20.62M(-61.8%)
Mar 2008
-
-$5.58M(-19.4%)
-$53.93M(+11.7%)
Dec 2007
-
-$6.93M(+68.9%)
-$48.29M(-3.2%)
Sep 2007
-
-$4.10M(-89.0%)
-$49.86M(+10.9%)
Jun 2007
-$26.82M(+41.4%)
-$37.32M(<-9900.0%)
-$44.97M(+23.6%)
Mar 2007
-
$65.00K(-100.8%)
-$36.38M(+0.8%)
Dec 2006
-
-$8.50M(-1175.4%)
-$36.09M(+34.1%)
Sep 2006
-
$790.40K(-102.8%)
-$26.92M(-1.5%)
Jun 2006
-$18.98M(+101.1%)
-$28.73M(-8264.7%)
-$27.33M(+100.5%)
Mar 2006
-
$351.90K(-47.5%)
-$13.63M(-1.4%)
Dec 2005
-
$670.70K(+78.8%)
-$13.82M(-3.6%)
Sep 2005
-
$375.10K(-102.5%)
-$14.33M(-1.5%)
Jun 2005
-$9.44M(+57.4%)
-$15.03M(-9470.5%)
-$14.56M(+143.3%)
Mar 2005
-
$160.40K(-0.9%)
-$5.98M(-1.4%)
Dec 2004
-
$161.80K(+7.4%)
-$6.07M(-1.5%)
Sep 2004
-
$150.70K(-102.3%)
-$6.16M(-1.4%)
Jun 2004
-$6.00M(+77.1%)
-$6.46M(-8954.7%)
-$6.25M(+81.7%)
Mar 2004
-
$72.90K(+1.5%)
-$3.44M(-1.6%)
Dec 2003
-
$71.80K(+10.6%)
-$3.49M(-1.6%)
Sep 2003
-
$64.90K(-101.8%)
-$3.55M(-1.4%)
Jun 2003
-$3.39M(+164.7%)
-$3.65M(<-9900.0%)
-$3.60M(-7728.4%)
Mar 2003
-
$16.70K(+7.7%)
$47.20K(+54.8%)
Dec 2002
-
$15.50K(+3.3%)
$30.50K(+103.3%)
Sep 2002
-
$15.00K
$15.00K
Jun 2002
-$1.28M(+194.2%)
-
-
Jun 2001
-$434.60K
-
-

FAQ

  • What is EyePoint Pharmaceuticals, Inc. annual EBITDA?
  • What is the all time high annual EBITDA for EyePoint Pharmaceuticals, Inc.?
  • What is EyePoint Pharmaceuticals, Inc. annual EBITDA year-on-year change?
  • What is EyePoint Pharmaceuticals, Inc. quarterly EBITDA?
  • What is the all time high quarterly EBITDA for EyePoint Pharmaceuticals, Inc.?
  • What is EyePoint Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
  • What is EyePoint Pharmaceuticals, Inc. TTM EBITDA?
  • What is the all time high TTM EBITDA for EyePoint Pharmaceuticals, Inc.?
  • What is EyePoint Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

What is EyePoint Pharmaceuticals, Inc. annual EBITDA?

The current annual EBITDA of EYPT is -$129.23M

What is the all time high annual EBITDA for EyePoint Pharmaceuticals, Inc.?

EyePoint Pharmaceuticals, Inc. all-time high annual EBITDA is $12.42M

What is EyePoint Pharmaceuticals, Inc. annual EBITDA year-on-year change?

Over the past year, EYPT annual EBITDA has changed by -$60.23M (-87.28%)

What is EyePoint Pharmaceuticals, Inc. quarterly EBITDA?

The current quarterly EBITDA of EYPT is -$61.69M

What is the all time high quarterly EBITDA for EyePoint Pharmaceuticals, Inc.?

EyePoint Pharmaceuticals, Inc. all-time high quarterly EBITDA is $21.02M

What is EyePoint Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?

Over the past year, EYPT quarterly EBITDA has changed by -$27.50M (-80.46%)

What is EyePoint Pharmaceuticals, Inc. TTM EBITDA?

The current TTM EBITDA of EYPT is -$187.14M

What is the all time high TTM EBITDA for EyePoint Pharmaceuticals, Inc.?

EyePoint Pharmaceuticals, Inc. all-time high TTM EBITDA is $12.42M

What is EyePoint Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

Over the past year, EYPT TTM EBITDA has changed by -$89.41M (-91.49%)
On this page